Everloop 5 Tablet contains Everolimus 5 mg, a high-potency mTOR inhibitor widely used in organ transplant medicine and certain oncology therapies. It is designed to prevent graft rejection by suppressing T-cell activation while controlling abnormal cell proliferation in selected cancer indications.
Everolimus works by modulating the mammalian target of rapamycin (mTOR) pathway, reducing immune overactivity and maintaining optimal graft survival. This tablet is ideal for patients requiring higher-dose immunosuppression under strict medical supervision.
Clinically, Everloop 5 Tablet is used in renal, liver, and other solid organ transplant regimens and in targeted oncology protocols, where precise dose titration is critical for efficacy and safety.
The tablet ensures accurate dosing, consistent bioavailability, and reliable therapeutic outcomes, making it suitable for hospital supply chains, transplant centers, oncology clinics, and specialty pharmacies that demand high-quality immunosuppressive therapy.